Compare Royal Bank of Canada (RY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs TransMedics Group Inc — how do they compare? Royal Bank of Canada trades at $191 (market cap $262.99B), while TransMedics Group Inc trades at $79.01 (market cap $2.74B). The key difference: Royal Bank of Canada is far larger — about 96× TransMedics Group Inc's market cap, and Royal Bank of Canada pays a 2.66% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Bank of Canada for 47 Days and TransMedics Group Inc for 24 Days on average.
| RY | TMDX | |
|---|---|---|
Market Cap | $262.99B | $2.74B |
Volume | 1,016,377 | 949,331 |
Sector | Financials | Health |
52-Week High | $217.87 | $150.42 |
52-Week Low | $143.64 | $61.99 |
Typical Hold Time | 47 Days | 24 Days |
Enterprise Value | $730.11B | $3.13B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $191.22, down 2.61% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $3.07 versus $2.89 expected, and robust profitability with a 32.01% net income margin. Revenue growth accelerated to $66.53B in 2025, and the company maintains a solid dividend, with recent payouts of $1.76 per share. Analyst sentiment is mixed, with a Buy consensus of 43% but technical indicators pointing to near-term pressure.
RY presents a value opportunity with a reasonable P/E of 17.2 and strong ROE of 17.2%, supported by earnings momentum and strategic initiatives like global transaction banking integration. Risks include stretched valuations relative to peers, a high EV/EBITDA of 23.52, and macroeconomic sensitivity. The stock's current price near support at $189 suggests potential stability, but investors should weigh fundamental strength against technical bearishness and sector headwinds.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
